Last Price$581.2(1.7%)
Market Cap$34.9B
127.3%
Peers median - 9.9%
(9.4%)
Peers median - (0.9%)
N/A
Peers median - 8.6%
(41.3%)
Peers median - (11.1%)
Competing with ARGX
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$34.9B | 5.8 | $49.8 91.4% overvalued | 52.2% | $2,258.9M | ($211.2M) | 127.3% | (9.4%) | 86.8% | (41.3%) | N/A | |
$129.5B | 5.8 | $140.7 72.0% overvalued | 21.7% | $11.0B | ($790.3M) | 11.5% | (7.2%) | 86.1% | (15.0%) | 10.7% | |
$73.2B | 6.4 | $980.0 44.0% undervalued | (29.4%) | $14.2B | $3,597.2M | 8.3% | 25.3% | 84.5% | 25.7% | 5.7% | |
$31.1B | 5.2 | $82.1 66.1% overvalued | 62.9% | $2,248.2M | ($42.6M) | 23.0% | (1.9%) | 85.6% | (7.2%) | 1,931.9% | |
$23.4B | 5.9 | $328.1 236.6% undervalued | 3.7% | €2,751.1M | (€229.8M) | (28.0%) | (8.4%) | 80.3% | (37.8%) | 1.3% | |
$14.6B | 5.5 | $63.4 93.8% undervalued | 12.7% | $2,263.9M | $2,769.0M | (3.8%) | 122.3% | 73.9% | 14.5% | 73.6% | |
$13.9B | 6.0 | $0.6 97.0% overvalued | 325.5% | $0.0 | ($142.1M) | N/A | N/A | N/A | (3,335.4%) | 1.9% | |
$13.7B | 7.8 | $500.2 63.8% undervalued | 26.6% | $2,877.4M | $1,080.6M | 23.6% | 37.6% | 89.2% | 65.4% | 4.7% | |
$13.5B | 6.7 | $41.9 40.6% overvalued | (16.7%) | $2,850.5M | $475.4M | 17.8% | 16.7% | 78.6% | 11.0% | 10.7% | |
$13.2B | 6.1 | $86.6 152.5% undervalued | (67.8%) | $3,229.0M | ($4,055.0M) | (52.9%) | (125.6%) | 52.3% | (97.7%) | 6.5% | |
$1,846.9M | 5.5 | $3,045.6 1,243.4% undervalued | 39.9% | $3,316.8M | ($1,041.0M) | 50.5% | (31.4%) | 83.7% | (43.2%) | 32.1% |
Compare ARGX Valuation Multiples with Peers
LTM
NTM
1Y Forward
2Y Forward
EV/Revenue
General
Valuation Multiple
Financial metrics
Company name
EV/Revenue
Revenue growth
EBITDA margin
Net Income margin
argenx SEARGX
N/A
198.6%
(60.5%)
(24.1%)
Median Peer Set
3.9x
10.0%
0.0%
(2.4%)
Alnylam Pharmaceuticals, Inc.ALNY
13.2x
23.0%
(38.6%)
(12.4%)
BeiGene, Ltd.BGNE
0.1x
73.7%
467.1%
(35.9%)
BioMarin Pharmaceutical Inc.BMRN
4.5x
18.0%
139.3%
15.0%
BioNTech SEBNTX
1.8x
(27.9%)
N/A
(24.2%)
Moderna, Inc.MRNA
2.1x
(52.7%)
(24.9%)
(110.0%)
Regeneron Pharmaceuticals, Inc.REGN
4.0x
8.3%
10.4%
31.1%
Royalty Pharma plcRPRX
9.0x
(3.8%)
(43.7%)
37.9%
Summit Therapeutics Inc.SMMT
N/A
N/A
(68.7%)
N/A
United Therapeutics CorporationUTHR
3.7x
23.6%
25.7%
41.5%
Vertex Pharmaceuticals IncorporatedVRTX
11.4x
11.7%
N/A
(4.9%)
Compare ARGX Valuation Multiples Dynamics with Peers
Crunching data... Almost there!
FAQ
1. How does argenx SE (ARGX) revenue growth compare to peers and the industry?
argenx SE (ARGX) revenue growth is 127.3%, compared to the peers' median of 9.9%.
2. How does argenx SE (ARGX) Free Cash Flow (FCF) margin compare to peers and the industry?
argenx SE (ARGX) FCF margin is (9.4%), compared to the peers' median of (0.9%).
3. How does argenx SE (ARGX) Total Debt to Equity ratio compare to peers and the industry?
argenx SE (ARGX) Total Debt to Equity ratio is N/A, compared to the peers' median of 8.6%.
4. How does argenx SE (ARGX) ROIC (Return on Invested Capital) compare to peers and the industry?
argenx SE (ARGX) ROIC is (41.3%), compared to the peers' median of (11.1%).